Big Pharma's internationalization of RandD to China

China's increasing integration into the global pharmaceutical value chain is occurring at a time when big pharma's traditional RandD model has entered a period of crisis, and when China faces significant challenges in providing healthcare for its huge and rapidly ageing population. Despite...

Full description

Saved in:
Bibliographic Details
Published in:European planning studies 2015-09, Vol.23 (9), p.1873-1894
Main Authors: Grimes, Seamus, Miozzo, Marcela
Format: Article
Language:English
Subjects:
China
Drugs
Interviews
Multinational enterprises
Pharmaceuticals
Population ageing
Research and development
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:China's increasing integration into the global pharmaceutical value chain is occurring at a time when big pharma's traditional RandD model has entered a period of crisis, and when China faces significant challenges in providing healthcare for its huge and rapidly ageing population. Despite China's ambitions of promoting its own pharmaceutical sector, it is likely to continue to depend for some time on significant contributions from foreign companies. While this situation provides considerable opportunities for big pharma companies to expand their markets in China, they are also hoping that offshoring aspects of their RandD to China may contribute to reconfiguring their current RandD model with its weak record of producing new drugs. Drawing on interviews with a small number of pharma RandD centres in Shanghai, patent analyses and industry reports, we provide insights into both the challenges and the opportunities associated with the early stages of establishing such centres in an emerging region with a rapidly growing market. This paper contributes towards a more nuanced view of the internationalization of RandD in emerging regions. Reproduced by permission of Taylor and Francis Ltd.
ISSN:0965-4313
DOI:10.1080/09654313.2015.1029442